AllergyNCT01611636
Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study
An observational study of Allergy and Autoimmune Diseases, run by Far Eastern Memorial Hospital at 1 site in Taiwan.
Trial summary
The incidence and prevalence of the allergic, autoimmune and rheumatic diseases are different all over the world. The relative impact of gene and environment on diseases can be revealed by studies from different populations. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Allergy, Autoimmune Diseases, Rheumatic Diseases
- How many people
- 138 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Jan 2012to 30 Dec 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: National Health Insurance Research Database Far Eastern Memorial Hospital clinical database
Who may be able to join
- subjects with ICD9 coding fulfilling study subjects
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
The incidence and prevalence of the allergic, autoimmune and rheumatic diseases are different all over the world. The relative impact of gene and environment on diseases can be revealed by studies from different populations. National Health Insurance database in Taiwan provides a wealth of epidemiology study, which can contribute to the understanding of these diseases. However, national health care database did not contain test results and clinical details. The database of the hospital records can provide complimentary clinical details. Via the comparison of databases of the National health Institutes and the investigators hospital, the investigators hope that the characteristics and outcomes of these patients can be better understood.
Read the detailed description
The incidence and prevalence of the allergic, autoimmune and rheumatic diseases are different all over the world. The relative impact of gene and environment on diseases can be revealed by studies from different populations.
National Health Insurance database in Taiwan provides a wealth of epidemiology study, which can contribute to the understanding of these diseases. However, national health care database did not contain test results and clinical details. The database of the hospital records can provide complimentary clinical details. Via the comparison of databases of the National health Institutes and the investigators hospital, the investigators hope that the characteristics and outcomes of these patients can be better understood.
Briefly, epidemiology of target disease such as age, sex, incidence and prevalence will be derived from national database. Medical source utilization such as medication and surgery related to target diseases is also available in national database, providing material for cost analysis. These data can be compared with hospital database to ensure validity and reliability.
The investigators study is intended to provide epidemiology of target disease and cost analysis. Interaction between diseases will also be explored.
Target diseases Allergic diseases: Asthma(ICD9 493.x),Steven-Johnson syndrome and other erythroderma (ICD9 695.x)
Autoimmune diseases: Thyroid disease (ICD9 246.x), Addison disease (ICD9 255.x), type 1 diabetes mellitus (250.x1)
Rheumatic diseases: gout (ICD9 274.x), SLE (ICD9 710.0 ), RA (ICD9 714.0), AS and spondylitis (ICD9 720.0\&720.x), Psoriasis and psoriatic arthritis (ICD9 696.0), scleroderma (ICD9 710.1), Sjogren's syndrome (ICD9 710.2), dermatomyositis (ICD9 710.3), polymyositis (ICD9 710.4), ANCA vasculitis (WG 446.4, MPA, CSS, PAN ICD9 446.0) or vasculitis 447.6, Behcet's disease(ICD9 136.1), Temporal arteritis(ICD9 446.5), Takayasu arteritis (ICD9 446.7), Henoch-Schonlein purpura (ICD9 287.0)
- Conditions
- Allergy, Autoimmune Diseases, Rheumatic Diseases
- Keywords
- allergy, autoimmune diseases, rheumatic diseases
- Medical subject headings
- Hypersensitivity, Autoimmune Diseases, Rheumatic Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of target diseases
Population at risk of target diseases in database will be assessed up to 10 years
Measured: Up to ten years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2012 (estimated)
- Study start1 Jan 2012
- Primary completion30 Dec 2019
- Study completion30 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AllergyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 138 participants (actual)
Sponsor and investigators
- Lead sponsor
- Far Eastern Memorial Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chien-Sheng Wu, Far Eastern Memorial Hospital
- Investigators
- ChienSheng Wu, Master, Principal investigator, Chief, Department of Rheumatic disease
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01611636
- Sponsor's protocol ID
- 100165-E
- Status last verified
- Jun 2020
- First submitted
- 26 May 2012
- Last updated
- 23 Jun 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No IPD sharing, only sharing by publication
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study
- ClinicalTrials.gov ID
- NCT01611636
- Acronym / sponsor ID
- 100165-E
- Conditions
- Allergy, Autoimmune Diseases, Rheumatic Diseases
- Keywords
- allergy, autoimmune diseases, rheumatic diseases
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 138 participants (actual)
- Lead sponsor
- Far Eastern Memorial HospitalUniversity, hospital or other
- Study start
- 1 Jan 2012 (actual)
- Primary completion
- 30 Dec 2019 (actual)
- Study completion
- 30 Dec 2019 (actual)
- First posted
- 5 Jun 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The incidence and prevalence of the allergic, autoimmune and rheumatic diseases are different all over the world. The relative impact of gene and environment on diseases can be revealed by studies from different populations. National Health Insurance database in Taiwan provides a wealth of epidemiology study, which can contribute to the understanding of these diseases. However, national health care database did not contain test results and clinical details. The database of the hospital records can provide complimentary clinical details. Via the comparison of databases of the National health Institutes and the investigators hospital, the investigators hope that the characteristics and outcomes of these patients can be better understood.
Detailed description
The incidence and prevalence of the allergic, autoimmune and rheumatic diseases are different all over the world. The relative impact of gene and environment on diseases can be revealed by studies from different populations.
National Health Insurance database in Taiwan provides a wealth of epidemiology study, which can contribute to the understanding of these diseases. However, national health care database did not contain test results and clinical details. The database of the hospital records can provide complimentary clinical details. Via the comparison of databases of the National health Institutes and the investigators hospital, the investigators hope that the characteristics and outcomes of these patients can be better understood.
Briefly, epidemiology of target disease such as age, sex, incidence and prevalence will be derived from national database. Medical source utilization such as medication and surgery related to target diseases is also available in national database, providing material for cost analysis. These data can be compared with hospital database to ensure validity and reliability.
The investigators study is intended to provide epidemiology of target disease and cost analysis. Interaction between diseases will also be explored.
Target diseases Allergic diseases: Asthma(ICD9 493.x),Steven-Johnson syndrome and other erythroderma (ICD9 695.x)
Autoimmune diseases: Thyroid disease (ICD9 246.x), Addison disease (ICD9 255.x), type 1 diabetes mellitus (250.x1)
Rheumatic diseases: gout (ICD9 274.x), SLE (ICD9 710.0 ), RA (ICD9 714.0), AS and spondylitis (ICD9 720.0\&720.x), Psoriasis and psoriatic arthritis (ICD9 696.0), scleroderma (ICD9 710.1), Sjogren's syndrome (ICD9 710.2), dermatomyositis (ICD9 710.3), polymyositis (ICD9 710.4), ANCA vasculitis (WG 446.4, MPA, CSS, PAN ICD9 446.0) or vasculitis 447.6, Behcet's disease(ICD9 136.1), Temporal arteritis(ICD9 446.5), Takayasu arteritis (ICD9 446.7), Henoch-Schonlein purpura (ICD9 287.0)
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- National Health Insurance Research Database Far Eastern Memorial Hospital clinical database
Key inclusion criteria (1 listed)
- subjects with ICD9 coding fulfilling study subjects
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Incidence of target diseases
Time frame: Up to ten years
Population at risk of target diseases in database will be assessed up to 10 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2020.
- Individual participant dataSharing planned: No. No IPD sharing, only sharing by publication
Related trials for Allergy
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ChienSheng Wu, Master principal investigator
Chief, Department of Rheumatic disease
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Allergy and Autoimmune Diseases, run by Far Eastern Memorial Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of target diseases (time frame: Up to ten years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2020.